Fig. 2.

Number of EEs reporting positive cost-effectiveness results for each treatment for CDI, according to specific treatment comparisons. Numbers below x-axis refer to the number of EEs reporting each treatment comparison. CDI Clostridium difficile infection, EE economic evaluation, FDX fidaxomicin, FMT faecal microbiota transplant, MTZ metronidazole, VNC vancomycin. ^aEE compared FDX with ‘no FDX’ strategy (VNC or MTZ) [37]. ^bCost-effectiveness conclusion unclear from publication [29]. ^cBoth FMT and MTZ were considered to be cost-effective [59]. ^dMTZ cost-effective vs. FMT, and FMT cost-effective vs. VNC [65]